Onkologie. 2009:3(2):83-87

Farmakotherapy of metastatic renal cell carcinoma

prof. MUDr. Bohuslav Melichar, Ph.D1, Hana Študentová2
1 Hemato-onkologická klinika FN a LF UP v Olomouci
2 Kardiochirurgická klinika FN a LF UP v Olomouci

Metastatic renal cell carcinoma has hitherto been considered a tumor poorly responsive to therapy. For more than a decade cytokines

(interferon-alpha and interleukin-2) were the only drugs with reproducible activity. In recent years, targeted agents have emerged with

significantly higher efficacy compared to cytokines. However, compared to other tumors we have still a relatively very limited number

of active agents available. Further clinical trials should evaluate how to optimally utilize the potential of these agents. These studies may

indicate whether the combination of targeted agents is superior to sequential therapy.

Keywords: renal cell carcinoma, targeted therapy, bevacizumab, everolimus, interferon-alpha, interleukin-2, sunitinib, sorafenib, temsirolimus.

Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Melichar B, Študentová H. Farmakotherapy of metastatic renal cell carcinoma. Onkologie. 2009;3(2):83-87.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken PM. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 1990; 144: 755-759. Go to original source... Go to PubMed...
    2. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417. Go to original source... Go to PubMed...
    3. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin N Am 1993; 20: 303-321. Go to original source...
    4. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-17. Go to original source...
    5. Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-alfa and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85: 1130-1136. Go to original source... Go to PubMed...
    6. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994; 54: 4233-4237.
    7. Papac RJ, Poo-Hwu WJ. Renal cell carcinoma: A paradigm of lanthanic disease. Am J Clin Oncol 1999; 22: 223-231. Go to original source... Go to PubMed...
    8. Lokich J. Spontaneous regression of metastatic renal cancer: case report and literature review. Am J Clin Oncol 1997; 20: 416-418. Go to original source... Go to PubMed...
    9. Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. Cancer 1977; 118: 538-542. Go to original source... Go to PubMed...
    10. Marcus SG, Choyke PL, Reiter R, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993; 150: 463-466. Go to original source... Go to PubMed...
    11. Wyczolkowski M, Klima W, Bieda W, Walas K. Spontaneous regression of hepatic metastases after nephrectomy and metastasectomy of renal cell carcinoma. Urol Int 2001; 66: 119-120. Go to original source... Go to PubMed...
    12. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1265-1271. Go to original source... Go to PubMed...
    13. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540. Go to original source... Go to PubMed...
    14. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-1659. Go to original source... Go to PubMed...
    15. Mickisch GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-970. Go to original source... Go to PubMed...
    16. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995; 154: 32-34. Go to original source... Go to PubMed...
    17. Gatenby RA, Gawlinski ET, Tangen CM, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res 2002; 62: 5218-5222.
    18. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-2266. Go to original source... Go to PubMed...
    19. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg W, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 1928-1935. Go to original source... Go to PubMed...
    20. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-2867. Go to original source... Go to PubMed...
    21. Williams BRG. Interferon-alfa and -beta: Basic principles and preclinical studies: In: eds. Principles and Practice of the Biologic Therapy of Cancer. Third ed. Lippincott Williams and Wilkins: Philadelphia, 2000: 194-208.
    22. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin N Am 1993; 20: 283-295. Go to original source...
    23. Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Results of a randomized controlled trial. Cancer 2007; 110: 2468-2477. Go to original source... Go to PubMed...
    24. Motzer RJ, Rakhit A, Ginsberg M, et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001; 19: 1312-1319. Go to original source... Go to PubMed...
    25. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002; 20: 3841-3849. Go to original source... Go to PubMed...
    26. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696. Go to original source... Go to PubMed...
    27. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997; 3: S70-S72. Go to PubMed...
    28. Murray Law T, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76: 824-832. Go to original source...
    29. Ravaud A, Delva R, Gomez F, et al. Subcutaneous interleukin-2 and interferon a in the treatment of patients with metastatic renal cell carcinoma - less efficacy compared with intravenous interleukin-2 and interferon a. Results of a multicenter phase II trial from the Groupe Francais d Immunotherapie. Cancer 2002; 95: 2324-2330. Go to original source... Go to PubMed...
    30. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141. Go to original source... Go to PubMed...
    31. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-3132. Go to original source... Go to PubMed...
    32. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1272-1278. Go to original source... Go to PubMed...
    33. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J Clin Oncol 1999; 17: 2039-2043. Go to original source... Go to PubMed...
    34. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A: S6-S8. Go to original source... Go to PubMed...
    35. Tourani JM, Pfister C, Berdah JF, et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa adminstration in combination with fluorouracil in patients with metastatic renal cell carcinoma: Results of a sequential nonrandomized phase II study. J Clin Oncol 1998; 16: 2505-2513. Go to original source... Go to PubMed...
    36. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-2980. Go to original source... Go to PubMed...
    37. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 2000; 18: 4009-4015. Go to original source... Go to PubMed...
    38. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2-and interferon-2alfa-based immunochemotherapy in advanced renal cell carcinoma: A prospective randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22: 1188-1194. Go to original source... Go to PubMed...
    39. Osband ME, Lavin PT, Babayan RK, et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990; 335: 994-998. Go to original source... Go to PubMed...
    40. Van den Eynde BJ, Gaugler B, Probst-Kepper M, et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med 1999; 190: 1793-1799. Go to original source... Go to PubMed...
    41. Childs R, Chernoff A, Contntin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloblative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758. Go to original source... Go to PubMed...
    42. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017-2024. Go to original source... Go to PubMed...
    43. Strair RK, Schaar D, Medina D, et al. Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. J Clin Oncol 2003; 21: 3785-3791. Go to original source... Go to PubMed...
    44. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434. Go to original source... Go to PubMed...
    45. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524. Go to original source... Go to PubMed...
    46. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial gorwth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24. Go to original source... Go to PubMed...
    47. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. Go to original source... Go to PubMed...
    48. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111. Go to original source... Go to PubMed...
    49. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428. Go to original source... Go to PubMed...
    50. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-1476. Go to original source... Go to PubMed...
    51. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. Go to original source... Go to PubMed...
    52. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748. Go to original source... Go to PubMed...
    53. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szcylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-67. Go to original source... Go to PubMed...
    54. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patieints with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918. Go to original source... Go to PubMed...
    55. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal Medicine 2007; 356: 2271-2281. Go to original source... Go to PubMed...
    56. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.